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Chronic kidneydisease is reachingepidemic proportionsworldwide and there is no effective treatment. Connective tissuegrowth factor
(CCN2) has been suggested as a risk biomarker and a potential therapeutic target for renal diseases, but its specific receptor has not
been identified. Epidermal growth factor receptor (EGFR) participates in kidneydamage, butwhether CCN2activates the EGFRpathway
is unknown. Here, we show that CCN2 is a novel EGFR ligand. CCN2 binding to EGFR extracellular domainwas demonstrated by surface
plasmon resonance. CCN2 contains four distinct structural modules. The carboxyl-terminal module (CCN2(IV)) showed a clear inter-
action with soluble EGFR, suggesting that EGFR-binding site is located in this module. Injection of CCN2(IV) in mice increased EGFR
phosphorylation in the kidney, mainly in tubular epithelial cells. EGFR kinase inhibition decreased CCN2(IV)-induced renal changes
(ERK activation and inflammation). Studies in cultured tubular epithelial cells showed that CCN2(IV) binds to EGFR leading to ERK ac-
tivation and proinflammatory factors overexpression. CCN2 interacts with the neurotrophin receptor TrkA, and EGFR/TrkA receptor
crosstalk was found in response to CCN2(IV) stimulation. Moreover, endogenous CCN2 blockade inhibited TGF-b-induced EGFR acti-
vation. These findings indicate that CCN2 is a novel EGFR ligand that contributes to renal damage through EGFR signalling.
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Introduction
Chronic kidney disease is a major health problem that has
reached epidemic proportions and it may lead to end-stage renal
disease or early cardiovascular death. Moreover, available clinical
treatments only retard renal disease progression. Connective
tissue growth factor (CCN2/CTGF), a member of the CCN (Cyr61/
CCN2/Nov) family, is over-expressed inmanyhuman renal patholo-
gies (Perbal, 2004; De Winter et al., 2008). Experimental studies
have shown that CCN2 inhibition slows disease progression in dia-
betic nephropathy, unilateral ureteral obstruction, and nephrecto-
mized TGF-b1 transgenic mice (Yokoi et al., 2004; Okada et al.,
2005;Guhaetal.,2007;Phanishetal.,2010) suggesting that thera-
peutic approaches that selectively block CCN2 activity could be
beneficial for renal disease treatment.
CCN2 has to be considered a matricellular protein rather than a
conventional growth factor. This protein, as other CNN members,
contains four distinct structural modules that can be cleaved by pro-
teases: an amino-terminal insulin-like growth-factor-binding
domain, a cysteine-rich domain, a thrombospondin type 1 repeat,
and a carboxyl-terminal cystine-knot domain (Rachfal and
Brigstock, 2005; Leask and Abraham, 2006; De Winter et al., 2008;
Chen and Lau, 2010). CCN2 and its degradation fragments have
been detected in biological fluids and have been proposed as risk
biomarkers in several nephropathies (Riser et al., 2003; Tam et al.,
2009; Slagman et al., 2011). Among these degradation fragments,
the 11 kDa carboxyl-terminal module (namely here CCN2(IV)) has
received special interest. In cultured cells, this fragment regulates
cell migration and proliferation, increases chemokines and extracel-
lularmatrix production, andhasbeen involved in renal inflammation
(Liu et al., 2006; DeWinter et al., 2008; Sanchez-Lopez et al., 2009;
Markiewicz et al.,2011). Although several studies have investigated
the intracellular mechanisms activated by CCN2 and its fragments,
the identification of a specific receptor for CCN2 remains elusive.
The epidermal growth factor receptor (EGFR) is the founding
member of the ErbB receptor tyrosine kinase family. EGFR signalling
controls key cellular programmes, including survival, proliferation,
differentiation, and locomotion, both during development and post-
natally. The EGFR is over-expressed, dysregulated, or mutated in
many epithelial malignancies, participating in human cancer includ-
ing lung, colon,breast,ovary,andgliomas(Sibiliaetal.,2007;Bronte
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Figure 1 CCN2 binds to EGFR. Surface plasmon resonance interaction analysis of full-length CCN2 (A) and the carboxyl-terminal CCN2 fragment
(CCN2(IV)) (B) with immobilized EGFR extracellular domain (sEGFR) was performed using Biacore 3000. Increasing concentrations of ligands (1–
250 nmol/L) were injected over a surface with a density of 500 response units (RU) of immobilized sEGFR. The response in RU was recorded as a
function of time. An overlay plot is shown of all sensorgrams after subtraction of their respective control sensorgrams. Binding parameters, cal-
culated by applying the nonlinear curve-fitting software package BIAevaluation 3.2 (BIAcore, Inc.) to all sensorgrams simultaneously using a
single-site model with drifting baseline, indicate that CCN2(IV)/EGFR interaction occurs with Kd ¼ 126+2 nmol/L. (C and D) CCN2(IV) interacts
with EGFR in human tubular epithelial cells. Fluorescent labelled CCN2(IV)-Cy5 (100 ng/ml) was added to HK2 cells and live confocal microscopy
imageswere taken once every 1.3 sec for a period of 2min (time 0 and 20 sec, C; time 2 min,D). Nuclei were stainedwith DAPI (blue). CCN2–EGFR
interactionwas evaluatedby immunocytochemistry. Serum-starvedHK2 cellswere stimulatedor notwith100 ng/mlCCN2(IV)-Cy5 (E) or CCN2(IV)
(F) for 10 min, and fixed by cross-linking. (E) CCN2(IV)-Cy5-treated cells presented a red membrane immunostaining, while EGFR was immunode-
tectedbyan secondaryAlexaFluorw488 labelled antibody (green). EGFR/CCN2(IV) colocalizationwas found (yellow staining,merge). (F) EGFRand
CCN2 were detected using specific primary antibodies followed by their corresponding secondary AlexaFluorw633/488 antibodies (red/green,
respectively). EGFR/CCN2 colocalization was found only in CCN2(IV)-treated cells (yellow staining), but not in control ones. Figures show a
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et al., 2011). Besides tumour biology, EGFR family members are
implicated in thedevelopment of endorgan damage inhypertension
(Hao et al., 2004) and atherosclerosis (Dreux et al., 2006). In the
kidney, EGFR signalling is critically involved in renal electrolyte
homeostasis (Melenhorst et al., 2008), and EGFR blockade, by
genetic or pharmacological approaches, ameliorates experimental
renal disease progression (Terzi et al., 2000; Lautrette et al., 2005;
Flamant et al., 2012; Liu et al., 2012). Our aim was to investigate
the capacity of CCN2 and its carboxyl-terminal fragment to interact
withandactivateEGFR,andwhether theactivationofEGFRsignalling
is involved in CCN2-induced responses in the kidney.
Results
CCN2 binds to EGFR via the carboxyl-terminal module
Surface plasmon resonance analysis was used to assess the
ability of CCN2 to bind the extracellular domain of EGFR. CCN2
bound to immobilized EGFR on a BIAcore sensor chip (Figure 1A).
The full-length CCN2 protein contains four distinct structural
modules (De Winter et al., 2008). Binding experiments using the
carboxyl-terminal degradation fragment CCN2(IV) as a ligand
showed a clear interaction with EGFR (Figure 1B), suggesting that
the EGFR-binding site is present in the carboxyl-terminal module.
To investigatewhetherCCN2directly interactswithEGFR incells,we
performed studies in cultured human tubular epithelial cells (HK2 cell
line). First, live-cell imaging by confocal time-lapse microscopy was
performed to visualize CCN2(IV) binding to the cell. After adding la-
belled CCN2(IV)-Cy5 to cells, the immunofluorescent signal was
rapidly located at the cell membrane, indicating CCN2(IV) cellular
binding (Figure 1C and D). The potential CCN2–EGFR interaction was
furtherdemonstratedbyimmunocytochemistryandimmunoprecipita-
tion (IP) experiments, using a cross-linking procedure to fix the pro-
teins anchored to the cell surface. EGFR is expressed in untreated
HK2 cells. Moreover, CCN2(IV)-treated cells showed a clear cellular
binding that colocalized with EGFR immunostaining (Figure 1E and
F). IP studies showed that inCCN2(IV)-treatedcells, but not inuntreat-
ed ones, CCN2–EGFR complexeswere formed (Figure 1GandH). One
of the earliest steps of EGFR activation is its auto-phosphorylation on
tyrosine (Y) residues (Sweeney and Carraway, 2000). In CCN2(IV)-
treatedcells,complexescontainingtyrosine-phosphorylatedproteins,
including Y1068 on EGFR,were found (Figure 1H). Transfectionwith a
small interfering RNAmolecule (siRNA) targeting EGFR, but notwith a
nonspecific scramble siRNA, abolished the CCN2–EGFR complex for-
mation, showing the specificity of this interaction (Figure 1G). These
data demonstrate that in cultured tubular epithelial cells, stimulation
with CCN2(IV) led to CCN2–EGFR complex formation.
CCN2 induces EGFR phosphorylation in cultured tubular epithelial
cells
In cultured human tubular epithelial cells, CCN2(IV) increased
EGFR phosphorylation on Y1068 and Y1173 (Figure 2A). In murine
tubular epithelial cells, CCN2 (IV)-induced EGFR activation was
dose- and time-dependent, starting as early as 5 min and peaking
after 15 min with a maximal response at 50 ng/ml (Figure 2B and
C). EGFR specific activation was demonstrated by pharmacological
inhibition using two different EGFR kinase inhibitors, erlotinib and
AG1478 (Figure 2D), and EGFR gene silencing (Figure 2E). CCN2(IV)
also increased EGFR phosphorylation in other cell types, including
murine fibroblasts and human mesangial cells (Figure 2F and G).
Moreover, the full-lengthCCN2proteinalso inducedEGFRphosphor-
ylation (Figure 2H), showing a similar response as obtainedwith the
carboxyl-terminal fragment CCN2(IV). For this reason, only CCN2(IV)
was used in the following experiments. Our data demonstrate that
both CCN2 and its carboxyl-terminal fragment bind and activate
EGFR signalling in cells.
CCN2(IV) induces EGFR phosphorylation in the kidney
Next, we investigated whether CCN2 could activate EGFR signal-
ling in the kidney. Renal levels of phosphorylated EGFR protein
were elevated in CCN2(IV)-injected mice compared with control
mice (Figure 3A). In the kidney, EGFR is mainly expressed in
tubular cells (Melenhorst et al., 2008). Immunohistochemistry
and immunofluorescence using antibodies that recognized phos-
phorylated EGFR on Y1173 and Y1068, respectively, revealed that
CCN2(IV) activated EGFR in tubular cells in vivo (Figure 3B, C, and
E). Treating the CCN2(IV)-injected mice with erlotinib, a small mol-
ecule tyrosine kinase inhibitor that targets the receptor catalytic
domain of EGFR, diminished renal phosphorylated EGFR levels to
control levels (Figure 3B, C, and E).
EGFR activation by CCN2(IV) is linked to ERK signalling
Several auto-phosphorylation sites have been identified in the
carboxyl-terminal region of EGFR that varies dependent on the
ligand and are linked to different downstream signalling systems
(Sweeney and Carraway, 2000). EGFR phosphorylation on Y1068
and Y1173 is involved in ERK signalling (Rojas et al., 1996;
Pourazar et al., 2008). Both tyrosines were phosphorylated in
kidneys of CCN2(IV)-injected mice (Figure 3) and in cultured
tubular epithelial cells exposed to CCN2(IV) (Figure 2A). CCN2(IV)-
injectedmicealsopresentedelevated renal levelsofphosphorylated
ERK1/2 compared with controls, which were inhibited by erlotinib
(Figure 3D). EGFR activation by CCN2 was also linked to ERK
signalling in cultured tubular epithelial cells. Blockade of EGFR, by
kinase inhibitionorgene silencing, diminishedERKphosphorylation
levels in CCN2(IV)-treated cells to levels similar to their correspond-
ing controls (Figure 2D and E).
CCN2(IV) via EGFR activation regulates renal inflammatory
response in vivo and in vitro
We further investigated the in vivo effect of EGFR blockade on
CCN2-induced renal damage. Treatment of CCN2(IV)-injected
mice with erlotinib diminished the presence of infiltrating mono-
cytes/macrophages (F4/801 cells) and T lymphocytes (CD31
representative experiment of four with similar results. (G) CCN2–EGFR complexes were found by coprecipitation experiments. Cell lysates were
immunoprecipitated with anti-CCN2, followed by SDS–PAGE and western blotting (IB) using an anti-EGFR antibody. In some points, cells were
transfectedwithanEGFRsiRNAor its corresponding scramble siRNA. InCCN2(IV)-treated cells, the170 kDabandcorresponding toEGFRmolecular
weight was found, while it disappeared in EGFR silenced cells, showing the formation of CCN2–EGFR complexes. The IB with anti-CCN2 antibody
was used as loading control. (H) IP with anti-EGFR antibody followed by IB with several antibodies: anti-phosphorylated tyrosine (PY20), anti-
phosphorylated EGFR (p-EGFR1068), anti-CCN2, and anti-EGFR (used as loading control). In CCN2(IV)-treated cells, bands for PY20, p-EGFR1068
and CCN2 were detected, confirming CCN2–EGFR complex formation. Figures show a representative IP experiment of five with similar results.
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Figure 2 CCN2 activates EGFR signalling in renal cells. EGFR activation was evaluated using antibodies against phosphorylated EGFR on Y1068
(p-EGFR1068) or Y1173 (p-EGFR1173), both implicated in ERK activation. CCN2(IV) increased EGFR phosphorylation in human (A) and murine (B–
D) tubular cells. (A) Human tubular epithelial cells (HK2 cells) were treated with 50 ng/ml CCN2(IV) for 15 min. Some cells were pre-incubated
with erlotinib (10 mmol/L). Murine tubular epithelial cells were treated with 10 ng/ml CCN2(IV) for increasing time periods (B) or with several
concentrations of CCN2(IV) (range 50–0.1 ng/ml) for 15 min (C). (D) Cells were pre-incubated for 1 h with erlotinib (10 mmol/L) or AG1478
(100 nmol/L) before the stimulation with 10 ng/ml CCN2(IV) for 15 min. (E) CCN2(IV) induces EGFR phosphorylation linked to ERK activation in
tubular epithelial cells. HK2 cells were incubated with transfection reagent alone (untransfected) or transfected with EGFR siRNA or scramble
siRNA, and then treated or not with CCN2(IV). ERK activity was determined by levels of phosphorylated ERK1/2. Total EGFR, ERK, and GAPDH
levels were used as loading/silencing controls. Data of phosphorylated protein vs. total protein levels are expressed as mean+SEM of 8 inde-
pendent western blot experiments. *P, 0.05 vs. control-untransfected. }P, 0.05 vs. untreated scramble siRNA-transfected cells. †P, 0.05 vs.
CCN2(IV)-treatedscramblesiRNA-transfectedcells. &P, 0.05vs.CCN2(IV)-treateduntransfectedcells.Renalfibroblasts (F) andhumanmesangial
cells (G) were treated with 10 ng/ml CCN2(IV) for 15 min and 50 ng/ml CCN2(IV) for increasing time periods (5, 10, and 15 min), respectively. (H)
Full-lengthCCN2activates theEGFRpathway.Murine tubularepithelial cellswerestimulatedwith34 ng/mlCCN2 (full-length recombinantprotein)
for increasing time periods. *P, 0.05 vs. control. #P, 0.05 vs. CCN2(IV) alone. Figures (except E) showa representativewestern blot experiment
and data are expressed as mean+SEM of 5–8 independent experiments.
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cells) in the kidney to levels similar to control mice (Figure 4A and
B). EGFR inhibition also down-regulated renal gene expression and
protein levelsof several proinflammatory factors (CCL-2and IL-6) to
control levels (Figure 4C and D).
In cultured murine tubular epithelial cells, CCN2(IV) regulates
some proinflammatory factors (Sanchez-Lopez et al., 2009). The
blockade of EGFR by erlotinib or AG1478 diminished CCN2(IV)-
induced gene overexpression and protein release of CCL-2 and
IL-6 to control levels (Figure 4E and F). Similar inhibitory effect
was found by EGFR gene silencing (Figure 4G). These data link
EGFRactivationbyCCN2(IV)with theup-regulationofproinflamma-
tory factors in tubular epithelial cells and the inflammatory re-
sponse observed in the kidney.
ADAMs are not involved in CCN2-mediated EGFR-signalling
activation
BesidesdirectactivationofEGFRby ligandbinding,several factors
can indirectly activate EGFR by a process termed ‘transactivation’.
EGFR transactivation is regulated by ADAMs, disintegrins, and
matrixmetalloproteases (MMPs) thatmediateEGFR ligandshedding
(Ohtsu et al., 2006). In renal cells, ADAM-17 regulates EGFR transac-
tivation (Lautrette et al.,2005;Wolf,2005).Wehaveobserved that a
pan-specific inhibitor of MMPs, GM6001, did not modify
CCN2(IV)-induced EGFR phosphorylation (Figure 5A). Moreover,
the pharmacological inhibition of ADAM-17 using TAPI-2 or
ADAM-17 gene silencing did not modify CCN2(IV)-induced EGFR
phosphorylation (Figure 5A and B). These data clearly demonstrate
that ADAMs are not involved in CCN2-mediated EGFR-signalling acti-
vation, and support our findings that CCN2 directly interacts with
EGFR.
Role of integrins in CCN2-induced EGFR activation
Integrins are heterodimeric receptors for cell-surface adhesion
molecules and extracellular matrix proteins, which are composed
of twosubunits,aandb. Eachabcombinationhasspecificsignalling
properties (Juliano, 2002). To date, eighteen a and eight b subunits
have been identified, which form at least 24 different ab integrins
(Humphries et al., 2006). Integrin-binding sites are present in CCN2
and mediate several effects (Chen et al., 2004; Gao and Brigstock,
2005).Wefirst tested the involvement of integrins in EGFR activation
Figure 3 CCN2 induces EGFR phosphorylation in the kidney. (A) C57BL/6 mice were i.p. injected with 2.5 ng/g of body weight of recombinant
CCN2(IV) or vehicle (saline) and sacrificed 24 h later. Some animals were treated with erlotinib (40 mg/kg per day) or its vehicle (control
group), starting 24 h before CCN2(IV) injection. EGFR activation was determined in total renal extracts by western blot analysis. Figure shows
two representative mice from each group and data are expressed as mean+SEM of 8–10 mice per group. The localization of activated EGFR
was determined by immunohistochemistry using antibody against p-EGFR1173 (B) and by immunofluorescence using antibody against
p-EGFR1068 (E), which showed increased p-EGFR immunostaining mainly in tubular epithelial cells. (C) The pEGFR1173 immunostaining in B was
quantified and expressed as mean+SEM of 8–10 animals per group. (D) ERK activation is a downstream mechanism of CCN2/EGFR signalling
in the kidney. Figure shows a representative experiment and data of p-ERK levels are expressed as mean+SEM of 8–10 mice per group. *P,
0.05 vs. control. #P, 0.05 vs. CCN2(IV).
CCN2 and EGFR in the kidney Journal of Molecular Cell Biology | 327
 at ELTE on A
pril 21, 2015
http://jmcb.oxfordjournals.org/
D
ow
nloaded from
 
by CCN2(IV) using arginine-glycine-aspartic acid (RGD) peptides.
RGD was originally identified as the sequence in fibronectin that is
a recognition site for a5b1 integrin, but it also recognizes a3b1,
a8b1, aVb1, aVb3, aVb5, aVb6, and a2bb3 integrins (Plow et al.,
2000). Pre-incubation of HK2 cells with cyclic RGD peptide
(GRGDSP), but not with control peptide (GRGDESP), reduced
CCN2(IV)-inducedEGFRactivation (Figure6A), suggesting that integ-
rins with RGD recognition specificity may be involved in CCN2
responses.
The specific integrins involved in CCN2 actions are cell-
dependent. In hepatic stellate cells, aVb3 integrin interacts with
CCN2(IV) (Gao and Brigstock, 2004), while in pancreatic stellate
cells it is a5b1 (Gao and Brigstock, 2005). Therefore, we tested
the involvement of these two integrins in tubular epithelial cells.
Pre-incubation of HK2 cells with a neutralizing antibody against
aVb3 integrin inhibited CCN2(IV)-induced EGFR phosphorylation,
while a control IgG or a a5b1-neutralizing antibody had no effect
(Figure 6B). Using siRNA against b3 or aV integrins showed
Figure 4 EGFR kinase inhibition decreases CCN2(IV)-induced renal inflammatory cell infiltration. In paraffin-embedded kidney sections, immuno-
histochemistry using anti-F4/80 and anti-CD3wasperformed to characterizemonocyte/macrophages and T lymphocytes, respectively (represen-
tative sections from each group, A; staining quantification, B). Magnification 200×. Erlotinib inhibits CCN2(IV)-induced up-regulation of renal
inflammatory molecules. CCL-2 and IL-6 gene expression levels were determined by real-time PCR (C) and protein levels by ELISA (D) in total
renal extracts from different animal groups. Data are expressed as mean+SEM of 8–10 animals per group. *P, 0.05 vs. control. #P, 0.05
vs. CCN2(IV). (E–G) CCN2(IV) increases proinflammatory factors via EGFR activation in murine tubular epithelial cells. Cells were pre-incubated
for 1 h with erlotinib (10 mmol/L) or AG1478 (100 nmol/L) before the stimulation with 10 ng/ml CCN2(IV) for 6 h (gene studies; E) or 24 h
(protein studies, cell-conditioned medium; F). (G) EGFR gene silencing inhibits upregulation of proinflammatory molecules caused by CCN2(IV)
in human tubular epithelial cells. HK2 cells were transfected or not with an EGFR or scramble siRNA before the stimulation with 50 ng/ml
CCN2(IV) for 6 h (gene studies). Data are expressed as mean+SEM of 6 (E), 5 (F), and 4 (G) independent experiments. *P, 0.05 vs.
control-untransfected. #P, 0.05 vs. CCN2(IV). †P, 0.05 vs. CCN2(IV)-treated scramble siRNA-transfected cells. &P, 0.05 vs.
CCN2(IV)-treated untransfected cells.
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similar inhibitory effects, while a scrambled siRNA had no effect
(Figure 6C andD). These data clearly show thataVb3 integrinmed-
iates CCN2(IV)-induced EGFR activation.
Next,weevaluatedwhetherCCN2(IV) coulddirectlybind toaVb3
integrin by IP experiments. In CCN2(IV)-treated HK2 cells, the for-
mation of CCN2-b3 and CCN2-aV complexes was found
(Figure 6E). Moreover, EGFR gene silencing did not modify the
CCN2(IV) binding toaV orb3 integrin subunits (Figure 6E), demon-
strating the direct binding of CCN2(IV) toaVb3 integrin, even in the
absenceof EGFR. Interestingly, pre-incubationof cellswith theneu-
tralizing antibody against aVb3 integrin did not modify the CCN2–
EGFR complex formation, assessed by EGFR co-IP upon CCN2(IV)
treatment (Figure6F). ThesedatashowedthataVb3 integrindirect-
ly binds to CCN2(IV), but is not necessary for the binding of
CCN2(IV) to EGFR and the subsequent complex formation.
Potential crosstalkbetweenEGFRandTrkA in response to CCN2(IV)
stimulation in cultured tubular epithelial cells
In mesangial cells, CCN2 stimulated tyrosine phosphorylation of
proteins at 75–80 and 140–180 kDa within 10 min, and previous
studies have identified the neurotrophin receptor TrkA (molecular
weight 140 kDa) as a potential CCN2 receptor (Wahab et al.,
2005), also in other cell types, such as cardiomyocytes (Wang
et al., 2010). Therefore, the role of TrkA in CCN2-induced responses
in tubularepithelial cellswasevaluated.Westernblotwasperformed
usinganantibody that recognizesTrkAphosphorylatedonY490, pre-
viously related to CCN2 responses in mesangial cells (Wahab et al.,
2005). We found that CCN2(IV) increased TrkA phosphorylation
levels in HK2 cells, which was abolished in TrkA-silenced cells
(Figure 7A), showing the specificity of this CCN2(IV) response.
Next, we further evaluated the potential interrelation between
EGFR and TrkA in HK2 cells. Gene silencing of TrkA diminished
CCN2(IV)-induced EGFR phosphorylation (Figure 7A). Moreover,
pharmacological inhibition of TrkA using K252a also blocked
CCN2(IV)-mediated EGFR activation (Figure 7B). On the other
hand, EGFR gene silencing inhibited TrkA phosphorylation
induced by CCN2(IV) (Figure 7C). These data indicate an EGFR/
TrkA receptor crosstalk.
CCN2 is a downstream mediator of TGF-b-induced EGFR activation
CCN2 is a downstream mediator of TGF-b-induced profibrotic
responses (Ruiz-Ortega et al., 2007). In HK2 cells, blockade of en-
dogenous CCN2 production by specific CCN2 gene silencing mark-
edly diminished TGF-b-induced EGFR phosphorylation after 24 h of
TGF-b incubation, comparedwith scramble siRNAcontrols (Figure8).
Our results confirmandextendpreviousdata, showing that CCN2 is a
downstream mediator of TGF-b-induced responses, including EGFR
signalling.
Discussion
By surface plasmon resonance, we have detected direct binding
of CCN2 to the immobilized extracellular fraction of EGFR.
Interestingly, both full-length CCN2 and CCN2(IV) bound to EGFR
and increased EGFR phosphorylation in cultured renal cells, sug-
gesting that the EGFR-binding site is present in the carboxyl-
terminal module. Our in vivo studies show that CCN2(IV) activates
EGFR/ERK pathway in the kidney, mainly in tubular epithelial cells.
Our in vitro studies in these cells demonstrate that CCN2(IV) rapidly
binds to the cellular membrane and leads to CCN2–EGFR complex
formation, increases EGFR phosphorylation, and activates down-
stream signalling mechanisms. Seven ligands for EGFR have been
identified so far: EGF, TGF-a, heparin binding EGF-like growth
factor, amphiregulin, betacellulin, epigen, and epiregulin (Dreux
et al., 2006). Data presenting here extend this list, suggesting
that CCN2 is another ligand for EGFR.
Ligand binding to EGFR induces a conformational change leading
to the formationof receptor homo- or heterodimers and subsequent
activationof the intrinsic tyrosinekinasedomainbyphosphorylation
of specific tyrosine residues within the cytoplasmic tail of the recep-
tor (SweeneyandCarraway,2000).Phosphorylationofdifferent tyro-
sine residues occurs upon binding of different ligands to the same
EGFR, leading to a variety of downstream signal transduction path-
ways that can be selectively activated (Sweeney and Carraway,
2000). Our in vivo data clearly demonstrated that CCN2(IV) adminis-
trationactivated renal EGFR, as shownby increased EGFRphosphor-
ylation,mainly in tubular epithelial cells. In these cells in vitro and in
Figure 5 Pharmacological inhibition ofMMPs or ADAM-17 and gene silencing of ADAM-17 do notmodify CCN2(IV)-induced EGFR phosphorylation
in human tubular epithelial cells. (A) HK2 cells were pre-incubated for 1 h with the pan-specific MMPs inhibitor GM6001 (1 mmol/L) or the
ADAM-17-specific inhibitor TAPI-2 (20 mmol/L) before the stimulation with 50 ng/ml CCN2(IV) for 15 min. Values are mean+SEM from at
least 6 independent experiments. *P, 0.05 vs. control. (B) HK2 cells were transfected with ADAM-17 siRNA or scramble siRNA, and then
treatedwith50 ng/mlCCN2(IV) for15 min.Valuesaremean+SEMfromat least4 independent experiments. *P, 0.05vs. control-untransfected.
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Figure 6 Role of integrins in CCN2(IV)-induced EGFR activation in cultured human tubular epithelial cells. HK2 cells were pre-incubated with
0.2 mmol/L RGDSP or its control peptide RGDESP (A) or with 5 mg/ml neutralizing antibodies against aVb3 integrin, a5b1 integrin, or their cor-
responding IgG1 control (B). *P, 0.05 vs. control. #P, 0.05 vs. CCN2(IV). HK2 cells were non-transfected or transfected with aV (C), b3 (D), or
scramble siRNA, and then treated or not with 50 ng/ml CCN2(IV) for 15 min. Figures showa representativewestern blot and data are expressed as
mean+SEM of 8 independent experiments. aV or b3 integrin was used as silencing control and GAPDH as loading control. *P, 0.05 vs.
control-untransfected. }P, 0.05 vs. untreated scramble siRNA-transfected cells. †P, 0.05 vs. CCN2(IV)-treated scramble siRNA-transfected
cells. &P, 0.05 vs. CCN2(IV)-treated untransfected cells. (E) EGFR gene-silenced cells were stimulated with CCN2(IV) and cross-linked, and
cell lysates were immunoprecipitated with anti-CCN2 antibody (IP) and analysed by western blot (IB) with antibodies against EGFR, CCN2, aV,
or b3 integrins. The formation of aV/b3-CCN2(IV) complexes in the presence or absence of EGFR (blocked by gene silencing) was shown. (F)
Cells were pre-incubated with a neutralizing aVb3 integrin antibody or IgG control before CCN2(IV) stimulation. The aVb3 integrin neutralization
did not modify CCN2(IV)-EGFR complex formation. One representative experiment out of three with similar results was shown in E and F.
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vivo, CCN2(IV) induced EGFR phosphorylation on Y1068 and Y1173,
which have been previously associated to MAPK cascade (Rojas
et al., 1996; Sweeney and Carraway, 2000). In cultured tubular epi-
thelial cells, EGFR blockade by gene silencing or kinase inhibition
inhibited CCN2(IV)-induced ERK activation and upregulation of
proinflammatory genes. In vivo treatment with erlotinib markedly
diminished the number of inflammatory cells, the up-regulation of
proinflammatory markers, and ERK activation in the kidneys of
CCN2(IV)-injected mice. Our results suggest that CCN2(IV) directly
binds to EGFR and activates its signalling pathway leading to the
modulation of downstream mechanisms, such as ERK activation,
and cellular responses, including renal inflammatory cell infiltration.
EGF ligands exist as inactive transmembrane precursors, requir-
ing ADAM-mediated proteolytic cleavage of their ectodomain to
be released as mature soluble ligands, whereby ADAMs regulate
EGFR ligands availability (Melenhorst et al., 2008). Regarding
CCN2, the full-length protein can be digested by proteases in-
cluding MMPs. In particular, MMP-2 leads to the generation of a
11 kDa carboxyl-terminal fragment, which corresponds to CCN2(IV)
(Hashimoto et al., 2002; De Winter et al., 2008; Tam et al., 2009).
In the urine of patients with diabetic nephropathy, full-length
CCN2 and CCN2(IV) were both found (Riser et al., 2003).
However, the mechanisms involved in the regulation of CCN2 deg-
radation in renal diseases are unknown and future studies are
needed.
EGFR transactivation is mediated by ADAM-dependent EGFR
ligand shedding by factors that bind G protein-coupled receptors
(Ohtsu et al., 2006). Depending on the tissue, different ADAMs
may be involved in EGFR ligand shedding. In this sense,
Angiotensin II-induced EGFR transactivation in the kidney is regu-
lated by ADAM-17 (Lautrette et al., 2005; Wolf, 2005; Flamant
et al., 2012), while ADAM-12 mediates this process in the heart
(Asakura et al., 2002). We have observed that the pharmacological
inhibition of MMPs or ADAM-17 and gene silencing of ADAM-17
did not modify CCN2(IV)-induced EGFR phosphorylation in renal
cells, demonstrating that MMPs are not involved in CCN2(IV)-
mediated EGFR-signalling activation and confirming the direct
interaction of CCN2(IV) with EGFR.
Several in vitro studieshave shownthat CCN2, through its binding
to different domains, regulates different processes. The aminus ter-
minal portion binds IGF-I and synergizes in the production of matrix
proteins in renal cells (Kimet al.,1997;Wang et al., 2001; Lamet al.,
2003). InXenopuscells,CCN2, throughthecysteine-richdomain,dir-
ectly binds to TGF-b and acts as a cofactor that enhances TGF-b
binding to its receptors and Smad-responsive promoter activation
(Abreu et al., 2002). TSP-1 domains have been implicated in the
binding to extracellularmatrix proteins, integrins, heparan sulphate
proteoglycans, low-density lipoprotein receptor-relatedprotein, and
vascular endothelial growth factor (Adams and Tucker, 2000;
Segarini et al., 2001; Inoki et al., 2002; Leask and Abraham, 2006;
Figure7Blockadeof TrkAbygenesilencingora specific TrkA receptor inhibitor inhibits CCN2(IV)-inducedEGFRactivationandEGFRgenesilencing
inhibits CCN2(IV)-induced TrkA activation. (A andC) HK2 cells were transfectedwith siRNA against TrkA (A) or EGFR (C) or its corresponding scram-
ble. (B) HK2 cells were pre-incubatedwith 1 × 1024 mmol/L K252a for 1 h. In all experiments, cells were treatedor notwith 50 ng/ml CCN2(IV) for
15 min.Activationof EGFRor TrkAwasevaluatedusing specificp-EGFR1068orp-TrkA490antibodies. EGFRandpTrkAwereusedassilencing controls
andGAPDHas loading control. Figures showa representativewestern blot experiment anddata are expressed asmean+SEMof4 (A),3 (B), and4
(C) independent experiments. *P, 0.05 vs. control-untransfected. }P, 0.05 vs. untreated scramble siRNA-transfected cells. †P, 0.05 vs.
CCN2(IV)-treated scramble siRNA-transfected cells. &P, 0.05 vs. CCN2(IV)-treated untransfected cells.
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Chen and Lau, 2010). The carboxyl-terminal CCN2 cystine-knot
module binds to integrins and exerts additional signalling capabil-
ities, including regulation of fibrosis and inflammation (Leask and
Abraham, 2006; Liu et al., 2006; De Winter et al., 2008). Our in
vitro data show that this carboxyl-terminal fragment binds to EGFR
leading to the regulation of proinflammatory factors. Our findings
implicate integrins as key mediators of CCN2(IV)-induced EGFR acti-
vation using RGD peptides and provide evidence that integrinaVb3
is involved in CCN2(IV)-induced EGFR activation based on results of
the in vitro experiments utilizing neutralizing anti-integrin anti-
bodies and siRNA. The ability of integrins to cooperatewith receptor
tyrosine kinases, including EGFR, to transduce proliferative signals
and regulate cell survival and migration has been discussed previ-
ously (Miranti and Brugge, 2002; Schwartz and Ginsberg, 2002).
Integrins are able to form physical complexes with EGFR at the cell
membrane and trigger ligand-independent phosphorylation of
Y845, Y1068, Y1086, and Y1173 residues in the EGFR molecule
(Moro et al., 1998). This integrin-dependent EGFR activation
appears necessary for full EGFR-dependent transcriptional
responses (Cabodi et al., 2004). Our data show that aVb3 integrin
binds to CCN2(IV) and is involved in EGFR-signalling transduction,
but is not necessary for its binding to the EGFR and the formation
of EGFR-CCN2(IV) complex.
TrkA is a member of the Trk family of cell membrane receptors
(TrkA, TrkB, and TrkC). These receptors interactwith neurotrophins
and form homodimers or heterodimers with the low-affinity pan
neurotrophin receptor, p75NTR. Neurotrophins, such as nerve
growth factor, brain-derived neurotrophic factor, neurotrophin 3
and 4, and their receptors, are important for the development, sur-
vival, and function of neurons (Allen andDawbarn, 2006). The neu-
rotrophin receptor TrkA has been proposed as a CCN2 receptor in
mesangial cells (Wahab et al., 2005) and involved in diabetic
nephropathy (Fragiadaki et al., 2012). In murine cardiomyocytes,
CCN2 via TrkA induced profibrotic and proinflammatory effects
(Wang et al., 2010). Interestingly, cardiomyocytes express add-
itional CCN2 receptors that mediate proinflammatory actions,
since CCN2-induced TNF-a and IL-6 mRNA upregulation occurred
in the absence of TrkA (Wang et al., 2010). In tubular epithelial
cells, we have found that CCN2(IV) activates TrkA signalling.
Gene silencing and pharmacological inhibition of TrkA diminished
EGFR phosphorylation, and EGFR gene silencing inhibited TrkA
phosphorylation induced by CCN2(IV), demonstrating EGFR/TrkA
crosstalk in response toCCN2(IV) stimulation. The similarityof phos-
phoproteomic profiles between TrkA and EGFR indicates a consider-
able overlap in downstream signallings originated in these tyrosine
kinase receptors (Bradshaw et al., 2013). In monocytes, EGFR/TrkA
crosstalk has been described in response to G protein-coupled
receptors and linked to modulation of proinflammatory mediators
(El Zein et al., 2010). The complexity of tyrosine kinase receptor sig-
nalling and interactions will require future studies.
The incidenceof chronic kidneydisease is increasing and current
treatments only retard disease progression. Many studies using
different strategies for blocking CCN2 activity have proven benefi-
cial effects on experimental pathologies, including renal diseases
(Leask and Abraham, 2006) However, these are far from being
used in humans. CCN2 overexpression has been described in a
wide variety of progressive human renal diseases and has been
proposed as a risk biomarker (Riser et al., 2003; Tam et al., 2009;
Slagman et al.,2011).Wedescribe here that CCN2 (both full-length
and the carboxyl-terminal fragment) interacts with and activates
EGFR, leading to ERK activation and regulation of renal inflamma-
tion. CCN2 has been described as a downstreammediator of profi-
brotic factors (Hashimoto et al., 2002; Ruperez et al., 2003; Leask
andAbraham, 2006). Our results showing that CCN2gene silencing
inhibited EGFR pathway activation in response to TGF-b support
these findings and extend the importance of EGFR signalling in
the fibrotic process. Experimental evidences suggest that EGFR in-
hibition may have therapeutic potential for kidney diseases
(Lautrette et al., 2005; Flamant et al., 2012; Liu et al., 2012). Our
findings indicate that CCN2 is a new ligand of the EGFR and identify
this receptor as an important therapeutic target for renal diseases.
Materials and methods
Cell cultures
Human renal proximal tubular epithelial cells (HK2 cell line, ATCC
CRL-2190) were grown in RPMI 1640mediumwith 10% fetal bovine
serum(FBS),1%glutamine,100 U/mlpenicillin,100 mg/mlstrepto-
mycin, 5 mg/ml insulin transferrin selenium (ITS), and 36 ng/ml
hydrocortisone in 5% CO2 at 378C. Murine renal cortical fibroblasts
(TFB cell line) and murine proximal tubular epithelial cells [murine
tubular-epithelial (MCT) cell line] originally obtained from Dr Eric
Neilson (Vanderbilt University) were grown in RPMI with 10% FBS,
2 mmol glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin in 5% CO2 at 378C. At 60%–70% of confluence, HK2 and
TFB cells were growth-arrested in serum-free medium for 24 h
Figure 8 Blockade of endogenous CCN2 production diminishes
TGF-b-induced EGFR activation. CCN2 gene silenced HK2 cells and
control cells were stimulated with 1 ng/ml TGF-b for 24 h. Figure
shows a representative experiment and data are expressed as mean+
SEMof3 independentwesternblot. *P, 0.05 vs. control-untransfected.
}P, 0.05 vs. untreated scramble siRNA-transfected cells. †P, 0.05 vs.
TGF-b-treated scramble siRNA-transfected cells. &P, 0.05 vs.
TGF-b-treated untransfected cells.
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before the experiments, whileMCT cellsweremaintained in1%FBS.
Reagents
The full-length molecule of CCN2 (CCN2; Biovendor), TGF-b and
CCN2(IV) (Preprotech), erlotinib (Vichem), tyrphostin AG1478
(Alomone Labs), K-252a and GM6001 (Calbiochem), TAPI-2 (Enzo
Life Sciences), RGDs peptides (Bachem), and neutralizing.
Neutralizing antibodies against integrin aVb3, integrin a5b1,
and IgG1 (Millipore) were used. DMSO, used as solvent of some
reagents, had no effect on cell viability or gene expression.
Ligand–receptor interaction assays
Surface plasmon resonance interaction analysis was performed
using Biacore 3000 (GE Healthcare). Data were collected using the
highest collection rate. All experiments were carried out at 258C
using HBS-EP (10 mmol/L HEPES, 150 mmol/L NaCl, 3 mmol/L
EDTA, 0.005% P20, pH 7.4) as running buffer. CM5 sensor chip,
N-hydroxysuccinimide (NHS), N-ethyl-N′-(3-dimethylaminopropyl)
carbodiimide (EDC), and ethanolamine HCl were obtained from
GE Healthcare. EGFR extracellular domain (Genway) was immobi-
lized on the surface of a CM5 sensor chip by the standard amino
coupling procedure at a flow rate of 5 ml/min. The surfacewas acti-
vated for 7 min using a 0.05 mol/L NHS/0.2 mol/L EDC mixture.
Then, 5 mg/ml EGFR in 10 mmol/L sodium acetate (pH 5.0) was
injected for 13 min. Finally, residual activated groups on the
surface were deactivated by a 7 min injection of 1 mol/L ethanola-
mine (pH 8.5). Immobilization density reached 500 RU. An add-
itional flow cell was activated and deactivated and then used as a
reference surface. For kinetic analysis, CCN2 and CCN2(IV) were
diluted in HBS-EP (range 1–250 mmol/L). Concentration series
and blank samples were injected for 3 min using a flow rate of
50 ml/min and the dissociation wasmonitored for 3 min. Data pro-
cessing and kinetic analysis were performed using BiaEvaluation
4.1.1. (GE Healthcare). Data were double referenced using refer-
ence surface subtraction and blank correction. Processed data
were globally fit to a simple 1:1 interaction model.
Live cell confocal microscopy
Cells were imaged using a Leica TCS SP5 confocal microscope.
Fluorophore Cy-5-emitted fluorescence was monitored with a
550+2 nm band pass or a 670 nm long pass filter and DAPI was
excited using a DIODE laser. For video rate confocal, the images
were captured (1 frame every 1.33 sec) at 400 Hz for a period of
2 min anddigitalized using the LIF/LEICAprogram (LEICAmicrosys-
tems). CCN2 fluorescence by Cy5 labellingwasdetected using Cy-5
fluorophore (1 nmol/ml; Amersham) following the manufacturer
instructions.
Chemical cross-linking
Chemical cross-linking was carried out as previously described,
using DTSSP (Pierce) (Ardura et al., 2010), before immunocyto-
chemistry and co-IP experiments.
Fluorescence immunocytochemistry
Growth-arrested HK2 cells growing on glass coverslips were sti-
mulated with CCN2(IV) or CCN2(IV)-Cy5. After chemical cross-
linking, cells were fixed in 4% paraformaldehyde, washed, and
blocked (PBS/10% BSA/4% serum, 1 h). Then, cells were incu-
bated overnight with anti-EGFR (1:200 dilution; Santa Cruz
Biotechnology) or anti-CCN2 (1:200 dilution; Sigma) in PBS with
1%BSA, followed by AlexaFluorw633-conjugated goat anti-mouse
(red) or AlexaFluorw488-conjugated goat anti-rabbit (green)
antibodies (1:300 dilution; Invitrogen), respectively. Nuclei were
stained with 1 mg/ml DAPI as control for equal cell density. The
absence of primary antibody was used as negative control.
Samples were mounted in Mowiol 40–88 (Sigma) and examined
by using a Leica DM-IRB confocal microscope.
Co-IP assays
After chemical cross-linking, cells were lysed in 300–500 ml
Triton–NP-40 lysis buffer [50 mmol/L Tris–HCl pH 8, 150mmol/L
NaCl, 1 mmol/L phenylmethylsulphonylfluoride, 1% NP-40/
IGEPAL, and a phosphatase-inhibitor cocktail (Set II, Calbiochem)],
scraped off the dish, and incubated for 1 h at 48C with shaking.
Cell lysates were pre-cleared by incubating with 10 ml of protein
A-agarose bead slurries (0.5 ml agarose/2 ml PBS) for 30min at
48C, and then centrifuged to wash away supernatants. Pre-cleared
lysates were incubated with 2.5–5 mg antibody overnight at 48C
for IPexperiment. The immunecomplexeswere capturedby theadd-
itionofproteinA/GPLUS-agarose (20 ml) beadslurries for1 hat48C.
The agarose beads were collected by centrifugation, washed and
subjected to SDS–PAGE, followed by western blot as described
below (Ardura et al., 2010).
Western blot
Proteins were obtained from treated cells or mouse kidneys
using lysis buffer (50mmol/L Tris–HCl, 150 mol/L NaCl, 2 mmol/L
EDTA, 2 mmol/L EGTA, 0.2% Triton X-100, 0.3% IGEPAL, 10 ml/ml
proteinase inhibitors cocktail,10 ml/ml PMSF, and 10 ml/ml ortho-
vanadate). To determine protein content the BCA method was
used. Cell (25 mg/lane) and kidney (100–150 mg/lane) protein
extracts were separated on 6%–12% polyacrylamide-SDS gels
under reducing conditions.
Samples were then transferred onto nitrocellulose membranes
(BioRad), blocked with TBS/5% defatted milk/0.05% Tween-20,
and incubated overnight at 48C with the following antibodies
(dilution): p-EGFR1068 (1:250; Calbiochem), p-EGFR1173 (1:250; Cell
Signalling), p-TrkA490 (1:1000; Cell Signalling), ADAM-17 (1:1000;
Abcam), CCN2 (1:1000; Sigma), EGFR (1:250), ERK 1/2 (1:200), in-
tegrin aV (1:200), integrin b3 (1:200), pERK1/2 (1:200), and anti-
phosphotyrosine PY20 (1:250; Santa Cruz). Membranes were
subsequently incubated with peroxidase-conjugated IgG secondary
antibody and developed using an ECL chemiluminiscence kit
(Amersham). Loading controls were done using an anti-GAPDHanti-
body (1:10000; Chemicon) or total protein levels in phosphorylation
studies. Autoradiographs were scanned using the Gel DocTM EZ
imager and analysed with the Image Lab 3.0 software (BioRad).
Gene silencing
Gene silencing in cultured cells was performed using either a
pre-designed siRNA corresponding to EGFR, ADAM-17, TrkA, CCN2
(Ambion), integrin aV, or integrin b3 (Santa Cruz Biotechnology)
or their corresponding scramble siRNAs. Subconfluent cells
were transfected for 24 h with 25 nmol/L siRNA using 50 nmol/L
Lipofectamine RNAiMAX (Invitrogen) or treated only with lipofecta-
mine—vehicle, according to the manufacturer’s instructions. Then,
cellswere incubatedwith10%heat-inactivatedFBSfor24 h, followed
by 24 h in serum-freemedium and then treated or notwith CCN2(IV).
Animal model
Studies were performed in adult male C57BL/6 mice (9–
12 weeks old, 20 g; Harlan Interfauna Ibe´rica) and maintained at
local animal facilities. All the procedures on animals were
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performed according to the European Community and Instituto de
Investigacio´n Sanitaria Fundacio´n Jime´nez Dı´az Animal Research
Ethical Committee guidelines. C57BL/6 mice received a single
intraperitoneal injection of recombinant CCN2(IV) (endotoxin
levels ,0.01 units; Preprotech) dissolved in saline at the dose of
2.5 ng/g of body weight as described (Sanchez-Lopez et al.,
2009), and studied 24 h later (n ¼ 8–10 mice per group). To
block EGFR activation, animals were treated with erlotinib
(40 mg/kg/day) or its vehicle (10% Ethanol) at 24 h before
CCN2 injection (n ¼ 8–10 mice per group). Mice were sacrificed
under anaesthesia (Ketamine-HCl/Xylazine-HCl) and then
kidneys were perfused in situ with cold saline before removal.
We have previously demonstrated that CCN2(IV) administration
did not cause tubular damage or fibrosis (Sanchez-Lopez et al.,
2009).
Renal histology and immunohistochemistry
Immunohistochemistry was carried out on 3 mm paraffin-
embedded kidney sections. Sections were deparafinized and
exposed to the PT Link (Dako) with Sodium Citrate Buffer
(10 mmol/L, pH 6 or 9 depending on the immunohistochemical
marker) for antigen retrieval. After endogenous peroxidase was
blocked, sections were incubated with 4% BSA/8% serum in 1×
wash buffer ‘en vision’ (Dako) to eliminate nonspecific protein
binding, followed by primary antibodies (dilution) F4/80 (1:50),
CD3 (1:300; Serotec), and p-EGFR1173 (1:200; Cell Signalling) over-
night at 48C. After washing, they were incubated with anti-IgG
secondary biotinylated-conjugated antibodies (Amersham) fol-
lowed by the avidin-biotin-peroxidase complex (Dako) and 3,3′-dia-
minobenzidine as chromogen. Sections were counterstained with
Carazzi’s haematoxylin.
Immunofluorescencewasperformedby incubating sectionswith
4% BSA/8% serum in PBS (for blockade), then anti-p-EGFR anti-
body (1:200; Dako), followed by AlexaFluorw633-conjugated anti-
body (1:200). The total number of positive stained cells was
quantified in five randomly chosen fields (20×) using the
Image-Pro Plus software. Data are expressed as positive stained
area vs. total analysed area. Triplicate samples from each animal
were examined in a blind manner.
ELISA for proinflammatory factors
CCL-2 and IL-6 protein levels were assayed by an ELISA kit
(eBioscience), and quantified by comparison with a standard
curve. Data are expressed as n-fold increase over the mean of
control levels.
Gene expression studies
Total RNAwas isolated fromcells andmouse kidney sampleswith
Trizol (Invitrogen). The cDNA was synthesized using the High-
Capacity cDNA Archive Kit (Applied Biosystems) using 2 mg of total
RNA primed with random hexamer primers. Multiplex real-time
PCR was performed using Applied Biosystems expression assays
mouse CCL-2 Mm00441242_m1 and mouse IL-6 Mm00446
190_m1. Data were normalized to 18S eukaryotic ribosomal RNA
4210893E (VIC). The mRNA copy numbers were calculated for each
sample by the instrument software using Ct value. Results are
expressed in copy numbers, calculated relative to unstimulated
cells or control mice, after normalization against 18S.
Statistical analysis
All results are expressed as mean+SEM. Differences between
agonist-treated groups and controls were assessed by Mann–
Whitney test. P, 0.05was considered significant. Statistical ana-
lysis was conducted using the SPSS statistical software (version
11.0).
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